Jane Street Group LLC Sells 89,957 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Jane Street Group LLC lessened its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 54.8% during the third quarter, HoldingsChannel reports. The fund owned 74,089 shares of the company’s stock after selling 89,957 shares during the quarter. Jane Street Group LLC’s holdings in PMV Pharmaceuticals were worth $110,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in PMVP. Point72 Asia Singapore Pte. Ltd. bought a new stake in PMV Pharmaceuticals during the 2nd quarter worth approximately $101,000. Evoke Wealth LLC purchased a new position in shares of PMV Pharmaceuticals during the second quarter valued at approximately $102,000. Cubist Systematic Strategies LLC grew its holdings in PMV Pharmaceuticals by 570.8% during the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company’s stock worth $113,000 after buying an additional 59,452 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in PMV Pharmaceuticals by 36.1% during the third quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company’s stock worth $527,000 after buying an additional 93,809 shares in the last quarter. Finally, BML Capital Management LLC raised its position in PMV Pharmaceuticals by 29.0% in the 3rd quarter. BML Capital Management LLC now owns 1,688,772 shares of the company’s stock valued at $2,516,000 after buying an additional 379,375 shares during the last quarter. Institutional investors and hedge funds own 90.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Oppenheimer raised shares of PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Friday, November 8th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $5.50.

PMV Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ PMVP opened at $1.35 on Wednesday. The company has a market capitalization of $69.86 million, a PE ratio of -1.35 and a beta of 1.46. The stock’s 50 day moving average price is $1.57 and its 200-day moving average price is $1.56. PMV Pharmaceuticals, Inc. has a twelve month low of $1.35 and a twelve month high of $2.26.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). As a group, research analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current fiscal year.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.